Junji Furuse

28.6k citations
421 papers · 12.7k · 7 hit papers · h-index 54

Impact in

  • Hepatology top 0.1%
    • Hepatocellular Carcinoma Treatment and Prognosis
  • Oncology top 0.2%
    • Pancreatic and Hepatic Oncology Research

Papers in

    • Pancreatic and Hepatic Oncology Research 168
    • Colorectal Cancer Treatments and Studies 37
    • Cholangiocarcinoma and Gallbladder Cancer Studies 134

Junji Furuse

396 papers receiving 12.5k citations

Junji Furuse's Hit Papers

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. 2022 · 259 citations
2590+5+10Years since publication250500750

Peers

Junji Furuse
Comparison fields: 5 of 134
  • Hepatology 3.9k
  • Oncology 6.6k
  • Cancer Research 2.2k
  • Pulmonary and Respiratory Medicine 3.7k
  • Surgery 4.7k
Replace Chris Verslype with:
Chris Verslype Belgium
Ghassan K. Abou‐Alfa United States
Arndt Vogel Germany
Masafumi Ikeda Japan
Daniel H. Palmer United Kingdom
Robin Kate Kelley United States
Alexis Laurent France
Arié Figer Israel
Jennifer J. Knox Canada
Tomoo Kosuge Japan
Junji Furuse relative to Chris Verslype Belgium Chris Verslype's profile →
Citations per field
00.5×1.5×
Chris Verslype · 1×
Citations per year

Countries citing papers authored by Junji Furuse

Since Specialization
Citations

This map shows the geographic impact of Junji Furuse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junji Furuse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junji Furuse more than expected).

Fields of papers citing papers by Junji Furuse

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junji Furuse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junji Furuse. The network helps show where Junji Furuse may publish in the future.

Co-authors

The 25 scholars most cited alongside Junji Furuse, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Junji Furuse Line = papers co-authored together Junji Furuse links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 421 papers — load more, or switch the sort, to bring in the rest.

#Work
1
The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
Hit paper breakdown →
2010790
2
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
Hit paper breakdown →
2010541
3
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
Hit paper breakdown →
2014449
4
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)
Hit paper breakdown →
2018379
5 2011322
6
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Hit paper breakdown →
2020274
7 2013267
8 2016264
9
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
Hit paper breakdown →
2022259
10 2012251
11
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
Hit paper breakdown →
2019247
12 2017206
13 2013180
14 2014179
15 2008163
16 2007155
17 2006151
18 2005149
19 2007139
20 2014130

About Junji Furuse

Junji Furuse is a scholar working on Oncology, Surgery, Pulmonary and Respiratory Medicine, Hepatology and Epidemiology, having authored 421 papers that have together received 12.7k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (168 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (134 papers), Hepatocellular Carcinoma Treatment and Prognosis (110 papers), Cancer Genomics and Diagnostics (66 papers), Neuroendocrine Tumor Research Advances (54 papers), Gallbladder and Bile Duct Disorders (49 papers), Colorectal Cancer Treatments and Studies (37 papers) and Cancer Mechanisms and Therapy (33 papers). The work is most often cited by research in Hepatology (3.9k citations), Oncology (6.6k citations), Cancer Research (2.2k citations), Pulmonary and Respiratory Medicine (3.7k citations) and Surgery (4.7k citations). Junji Furuse has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Takuji Okusaka, Hiroshi Ishii, Masafumi Ikeda, Laura Ladrón de Guevara, Christos N. Papandreou, Alan P. Venook, Chigusa Morizane, Masatoshi Kudo, Makoto Ueno and Kohei Nakachi. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Japanese Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology and Cancer Science.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact